416 related articles for article (PubMed ID: 28500811)
1. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
Shim E
Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
[TBL] [Abstract][Full Text] [Related]
2. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
Lee JS; Lourenço J; Gupta S; Farlow A
Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874
[TBL] [Abstract][Full Text] [Related]
3. Dengue dynamics and vaccine cost-effectiveness in Brazil.
Durham DP; Ndeffo Mbah ML; Medlock J; Luz PM; Meyers LA; Paltiel AD; Galvani AP
Vaccine; 2013 Aug; 31(37):3957-61. PubMed ID: 23791696
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dengue vaccination in ten endemic countries.
Zeng W; Halasa-Rappel YA; Baurin N; Coudeville L; Shepard DS
Vaccine; 2018 Jan; 36(3):413-420. PubMed ID: 29229427
[TBL] [Abstract][Full Text] [Related]
7. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines.
Shim E
Am J Trop Med Hyg; 2016 Nov; 95(5):1137-1147. PubMed ID: 27601519
[TBL] [Abstract][Full Text] [Related]
8. The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.
Shafie AA; Yeo HY; Coudeville L; Steinberg L; Gill BS; Jahis R; Amar-Singh Hss
Pharmacoeconomics; 2017 May; 35(5):575-589. PubMed ID: 28205150
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
[TBL] [Abstract][Full Text] [Related]
10. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
Aguiar M; Stollenwerk N; Halstead SB
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
[TBL] [Abstract][Full Text] [Related]
11. Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.
España G; Yao Y; Anderson KB; Fitzpatrick MC; Smith DL; Morrison AC; Wilder-Smith A; Scott TW; Perkins TA
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007482. PubMed ID: 31260441
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
[TBL] [Abstract][Full Text] [Related]
14. Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
Yang Y; Meng Y; Halloran ME; Longini IM
Clin Infect Dis; 2018 Jan; 66(2):178-184. PubMed ID: 29020332
[TBL] [Abstract][Full Text] [Related]
15. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
Flasche S; Jit M; Rodríguez-Barraquer I; Coudeville L; Recker M; Koelle K; Milne G; Hladish TJ; Perkins TA; Cummings DA; Dorigatti I; Laydon DJ; España G; Kelso J; Longini I; Lourenco J; Pearson CA; Reiner RC; Mier-Y-Terán-Romero L; Vannice K; Ferguson N
PLoS Med; 2016 Nov; 13(11):e1002181. PubMed ID: 27898668
[TBL] [Abstract][Full Text] [Related]
16. Current issues in the economics of vaccination against dengue.
Tozan Y
Expert Rev Vaccines; 2016; 15(4):519-28. PubMed ID: 26642099
[TBL] [Abstract][Full Text] [Related]
17. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
[TBL] [Abstract][Full Text] [Related]
18. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
[TBL] [Abstract][Full Text] [Related]
19. Vaccines and immunization strategies for dengue prevention.
Liu Y; Liu J; Cheng G
Emerg Microbes Infect; 2016 Jul; 5(7):e77. PubMed ID: 27436365
[TBL] [Abstract][Full Text] [Related]
20. Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.
El Fezzazi H; Branchu M; Carrasquilla G; Pitisuttithum P; Perroud AP; Frago C; Coudeville L
Am J Trop Med Hyg; 2017 Dec; 97(6):1898-1903. PubMed ID: 29141713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
